Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol Bioavailability and Mass Balance Study
NCT05874336Phase 1Completed
- Sponsor
- Galmed Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aramchol in Nonalcoholic steatohepatitis (NASH), sponsored by Galmed Pharmaceuticals. Primary endpoints: Absolute bioavailability at 10 days, Mass balance recovery at 10 days and 1 more. Started Jun 2020; status: completed.
02
Drugs
aramchol
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05874336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874336.